Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRDMT1 | O14717 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276197 | 0.92 | TRDMT1 (0.60) | TRDMT1ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL14696730 | 0.91 | ADORA1 (0.60) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL13269088 | 0.91 | ADORA1 (0.62) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL62486 | 0.91 | ADORA1 (0.65) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL932846 | 0.91 | ADORA1 (0.65) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL6907702 | 0.89 | METTL3 (0.70) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL4541368 | 0.89 | ADORA1 (0.64) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL13269154 | 0.89 | PDE2A (0.66) | TRDMT1ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL13269131 | 0.89 | ADORA1 (0.62) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 | |
| SCHEMBL622588 | 0.89 | ADORA1 (0.69) | ADORA1P2RY1SMN1; SMN2P2RY2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ACADEMIA SINICA (TW) | 2019-07-09 | — | — | US | disclosed |
| EP-2498774-B1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | ACADEMIA SINICA (TW) | 2017-10-11 | — | — | EP | disclosed |
| CN-106377540-A | Bifunctional compounds binding to adenosine A2A receptors and adenosine transporters for the prevention and treatment of neurodegenerative diseases | 中央研究院 | 2017-02-08 | — | — | CN | disclosed |
| CN-102740849-B | Bifunctional compounds binding to adenosine A2A receptors and adenosine transporters for the prevention and treatment of neurodegenerative diseases | ACADEMIA SINICA (CN) | 2016-11-30 | — | — | CN | disclosed |
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2015-12-31 | — | — | US | disclosed |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2012-11-22 | — | — | US | disclosed |
| CN-102740849-A | Binding to adenosine A2ABifunctional compounds of receptor and adenosine transporter for preventing and treating neurodegenerative diseases | ACADEMIA SINICA | 2012-10-17 | — | — | CN | disclosed |
| EP-2498774-A1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Academia Sinica (TW) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012064340-A1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | ACADEMIA SINICA (TW) | 2012-05-18 | — | — | WO | disclosed |
| EP-2021797-A4 | COMPOSITIONS OF N-Ý2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL¨-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMA (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2021797-A2 | COMPOSITIONS OF N-Ý2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL¨-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | Vertex Pharmaceuticals, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007134279-A2 | COMPOSITIONS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | TRDMT1 1048/4885ADORA1 2/4885P2RY1 188/4885 |
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ADORA2A, ADORA1, ADORA3 | TRDMT1 1048/4885ADORA1 2/4885P2RY1 188/4885 |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | TRDMT1 1048/4885ADORA1 2/4885P2RY1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.